However, according to Porter et al., overall response rate in CLL patients when treated with CTL019 (CD19 scFv+ 4-1BB costimulatory domain) was found to be 8/14 (57%), where 4 patients showed complete remissions (CR) and 4 showed partial remissions (PR). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.